BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. Expert Review of Vaccines 2017;16:577-86. [DOI: 10.1080/14760584.2017.1322514] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. Expert Rev Vaccines 2020;19:661-86. [PMID: 32741232 DOI: 10.1080/14760584.2020.1791093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
2 Chumakov K, Ehrenfeld E, Agol VI, Wimmer E. Polio eradication at the crossroads. Lancet Glob Health 2021;9:e1172-5. [PMID: 34118192 DOI: 10.1016/S2214-109X(21)00205-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: part 2. exploration of the potential role of vaccines in control and eradication. Expert Rev Vaccines 2021;20:449-60. [PMID: 33599178 DOI: 10.1080/14760584.2021.1891889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kalkowska DA, Thompson KM. Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan. Risk Anal 2021;41:266-72. [PMID: 32144841 DOI: 10.1111/risa.13471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
5 Thompson KM. Polio endgame options: will we have the vaccines needed? The Lancet 2019;394:99-100. [DOI: 10.1016/s0140-6736(19)31294-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Thompson KM, Kalkowska DA. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). Expert Rev Vaccines 2019;18:725-36. [PMID: 31248293 DOI: 10.1080/14760584.2019.1635463] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
7 Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, Thompson KM. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine 2021:S0264-410X(21)00473-4. [PMID: 33962838 DOI: 10.1016/j.vaccine.2021.04.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 Korotkova E, Laassri M, Zagorodnyaya T, Petrovskaya S, Rodionova E, Cherkasova E, Gmyl A, Ivanova OE, Eremeeva TP, Lipskaya GY, Agol VI, Chumakov K. Pressure for Pattern-Specific Intertypic Recombination between Sabin Polioviruses: Evolutionary Implications. Viruses 2017;9:E353. [PMID: 29165333 DOI: 10.3390/v9110353] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
9 Kalkowska DA, Franka R, Higgins J, Kovacs SD, Forbi JC, Wassilak SGF, Pallansch MA, Thompson KM. Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria. Risk Anal 2021;41:289-302. [PMID: 32348621 DOI: 10.1111/risa.13485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Tebbens RJD, Thompson KM. Using integrated modeling to support the global eradication of vaccine-preventable diseases. Syst Dyn Rev 2018;34:78-120. [PMID: 34552305 DOI: 10.1002/sdr.1589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Kalkowska DA, Pallansch MA, Cochi SL, Kovacs SD, Wassilak SGF, Thompson KM. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart. Risk Anal 2021;41:320-8. [PMID: 32632925 DOI: 10.1111/risa.13555] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
12 Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine 2021:S0264-410X(21)00543-0. [PMID: 33994237 DOI: 10.1016/j.vaccine.2021.04.061] [Reference Citation Analysis]
13 Duintjer Tebbens RJ, Hampton LM, Thompson KM. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. BMC Infect Dis 2018;18:165. [PMID: 29631539 DOI: 10.1186/s12879-018-3074-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
14 Thompson KM, Kalkowska DA. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. Risk Anal 2021;41:229-47. [PMID: 32339327 DOI: 10.1111/risa.13484] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
15 Kalkowska DA, Thompson KM. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV. Risk Anal 2021;41:312-9. [PMID: 32936466 DOI: 10.1111/risa.13590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Thompson KM, Kalkowska DA. Potential Future Use, Costs, and Value of Poliovirus Vaccines. Risk Anal 2021;41:349-63. [PMID: 32645244 DOI: 10.1111/risa.13557] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
17 Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, Oberste MS, Wassilak SGF, Badizadegan K, Thompson KM. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. Risk Anal 2021;41:329-48. [PMID: 33174263 DOI: 10.1111/risa.13622] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
18 Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines 2018;17:739-51. [PMID: 30056767 DOI: 10.1080/14760584.2018.1506333] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
19 Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, Hampton LM, Martinez M, Wassilak SGF, Thompson KM. Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations. Risk Anal 2018;38:1701-17. [PMID: 29314143 DOI: 10.1111/risa.12962] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]